Evidence map›Paper›PMID 41501105›Full record

ArticleScientific reports2026

A self-supervised machine learning pipeline for extracting information from live cell images at multiple doses and timepoints.

Dmitry Yu Isaev, Wen Pei Liu, Marc Cuevas, Yubo Tang, Kenny Ang, Chris Wilson, Quynh Mai, Jovani Adra, Allan Cruz, Khoi Nguyen and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dmitry Yu IsaevSoley Therapeutics Inc., South San Francisco, USA. disaev@soley.ai.
Wen Pei LiuSoley Therapeutics Inc., South San Francisco, USA.
Marc CuevasSoley Therapeutics Inc., South San Francisco, USA.
Yubo TangSoley Therapeutics Inc., South San Francisco, USA.
Kenny AngSoley Therapeutics Inc., South San Francisco, USA.
Chris WilsonSoley Therapeutics Inc., South San Francisco, USA.
Quynh MaiSoley Therapeutics Inc., South San Francisco, USA.
Jovani AdraSoley Therapeutics Inc., South San Francisco, USA.
Allan CruzSoley Therapeutics Inc., South San Francisco, USA.
Khoi NguyenSoley Therapeutics Inc., South San Francisco, USA.
Michael RicasaSoley Therapeutics Inc., South San Francisco, USA.
Ankur GuptaSoley Therapeutics Inc., South San Francisco, USA.
Mehrdad HamadaniSoley Therapeutics Inc., South San Francisco, USA.
Deepa SridharanSoley Therapeutics Inc., South San Francisco, USA.
Yerem YeghiazariansSoley Therapeutics Inc., South San Francisco, USA.
Kurosh AmeriSoley Therapeutics Inc., South San Francisco, USA. kameri@soley.ai.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Live cells are complex information-processing systems that continuously sense their environment and respond dynamically. However, conventional endpoint assays typically require fixation or cell destruction and fail to capture complex temporal changes. Live brightfield imaging offers a scalable, label-free solution that remains underutilized due to particularly low contrast, acute technical batch sensitivity, and the limited availability of robust computational methods for this modality. Leveraging recent self-supervised learning developments, we introduce Live Cell Dynamics (LCD), a novel end-to-end transformer-based pipeline, using novel plane-agnostic augmentation (treating different focal planes as views of the same state) and incorporating cross-batch sampling. LCD addresses brightfield modality challenges and extracts subtle dose- and time-dependent live cell states. Through systematic ablation we evaluate each self-supervised training innovation on a single cell line, measuring phenotypic activity (mean Average Precision) and Mechanism of Action (MoA) classification (F1-score), with 189 compounds in pre-training and 81 in holdout spanning ten MoAs. Our approach outperforms ablated baselines across all doses and timepoints for activity and MoA classification, enables compound polypharmacology detection from multi-dose/timepoint profiles, and supports unsupervised nuclei detection and counting. It leads to training foundation models from continuous live brightfield imaging to detect subtle live cell state changes, enabling scalable, cost-effective drug development.

Indexed as

Image Processing, Computer-AssistedSupervised Machine LearningCellsDrug DevelopmentHumansMicroscopyTime Factors

Identifiers

PMID41501105
PMCPMC12783685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.